ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Financing Was Obvious and Inevitable

<< Previous

Bullboard Posts

Next >>

Comment by M101on Sep 04, 2023 11:19am

103 Views

Post# 35618730

RE:RE:RE:Financing Was Obvious and Inevitable

We get it Bball, you're very wealthy and could easily afford to load up at the new low, congratulations. Your interests align with the Boston group's so the financing delay, lack of promotion under the replaced CEO and instantlly sold-out rallies are all good for you, therefore any talk about any of it being planned by those who benefitted most is gobblegook.

And what is the irreponsible accusation?

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?